Supernus Pharmaceuticals (SUPN) Depreciation & Amortization (CF) (2011 - 2026)

Supernus Pharmaceuticals has reported Depreciation & Amortization (CF) for 16 years, with the latest figure at $25.7 million in Q2 2026.

• Depreciation & Amortization (CF) for Q2 2026 came in at $25.7 million, up 20.55% year-over-year; the trailing twelve-month figure through Jun 2026 was $101.7 million (up 26.04% YoY), and the FY2025 annual result was $91.6 million, up 13.86% from the prior year.
• Depreciation & Amortization (CF) eased to $25.7 million in Q2 2026, from $26.1 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $26.1 million in Q1 2026 and troughed at $18.8 million in Q4 2024.
• A 5-year average of $21.9 million and a median of $21.4 million in 2022 frame the typical range for Depreciation & Amortization (CF).
• The widest annual swing landed in 2022, when Depreciation & Amortization (CF) soared 226.22%; it then slipped 13.06% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $20.8 million in 2022, then advanced by 3.97% to $21.7 million in 2023, then declined by 13.06% to $18.8 million in 2024, then jumped by 32.75% to $25.0 million in 2025, then climbed by 2.92% to $25.7 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $25.7 million in Q2 2026, $26.1 million in Q1 2026, and $25.0 million in Q4 2025.